Litcius/Paper detail

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

Masakazu Toi, Shigeru Imoto, Takanori Ishida, Yoshinori Ito, Hiroji Iwata, Norikazu Masuda, Hirofumi Mukai, Shigehira Saji, Akira Shimizu, Takafumi Ikeda, Hironori Haga, Toshiaki Saeki, Kenjiro Aogi, Tomoharu Sugie, Takayuki Ueno, Takayuki Kinoshita, Yuichiro Kai, Masahiro Kitada, Yasuyuki Sato, Kenjiro Jimbo, Nobuaki Sato, Hiroshi Ishiguro, Masahiro Takada, Yasuo Ohashi, Shinji Ohno

2020The Lancet Oncology62 citationsDOI

Topics & Concepts

MedicineBreast cancerClinical endpointInternal medicineInterim analysisAdjuvant therapyOncologyAromatase inhibitorSentinel lymph nodeSurgeryCancerClinical trialTamoxifenBreast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies